摘要
Abstract
The rapid development of chimeric antigen receptor T cell(CAR-T)immunotherapy has brought new light to the treatment of multiple myeloma(MM),among which B cell mature antigen is one of the most popular and successful target.BCMA-targeted CAR-T therapy has demonstrated deep and durable remissions of myeloma symptoms,a breakthrough in the treatment of relapsed refractory multiple myeloma(RRMM).However,due to antigen escape,CAR-T failure and other factors,most patients will still progress or relapse,and there is a lack of standard follow-up therapies for RRMM patients after BCMA-targeted CAR-T therapy.Furthermore,the complex,expensive and time-consuming manufacturing process of personalized CAR-T also limits its clinical efficacy and application.In view of the above challenges,this review summarizes the limitations and mechanisms of BCMA-targeted CAR-T therapy,combined with the latest advances in the field of MM therapy,and proposes potential optimal treatment strategies to further improve progression or outcomes in RRMM patients.关键词
B细胞成熟抗原/CAR-T疗法/复发难治性多发性骨髓瘤/耐药性Key words
B cell mature antigen/CAR-T therapy/Relapsed refractory multiple myeloma/Resistance
